The Drug Rediscovery Protocol (DRUP Trial)
This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also
| Condition(s) | Cancer, Tumors, Neoplasm, Neoplasia |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs\* prescribed for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic or protein expression test. The study also aims to simplify patient access to approved targeted therapies that are contributed to the program by collaborating pharmaceutical companies and to perform next generation sequencing on tumor biopsies for biomarker analyses. Eligible patients have an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma for which standard treatment options are no longer available and acceptable performance status and organ function. A genomic or protein expression test must ha |
| Who can participate | Inclusion Criteria: 1. Adult (age \>18 years) patient with a histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphomawith symptomatic disease progression or progression according to RECIST-criteria after standard anti-cancer treatment or for whom no such treatment is available or indicated. \* For patients with a primary brain tumor: Histologically confirmed recurrent or de novo primary brain tumor, with unequivocal progression after prior therapy, at least 3 months after radiotherapy (either first line chemo-radiotherapy or re-irradiation), and with stable or decreasing dosage of steroids for at least 7 days prior to the baseline MRI scan. 2. ECOG performance status 0-2 3. Patients must have acceptable organ function as defined belo |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | The Netherlands Cancer Institute |
| Locations | Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands; Amsterdam, Netherlands; Amsterdam, Netherlands; Amsterdam, Netherlands (+30 more sites) |
| Start date | 2016-08 |
| NCT ID | NCT02925234 |
| Official listing | https://clinicaltrials.gov/study/NCT02925234 |